WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018144514) TNF SUPERFAMILY FUSION POLYPEPTIDES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/144514 International Application No.: PCT/US2018/016100
Publication Date: 09.08.2018 International Filing Date: 31.01.2018
IPC:
C07K 14/525 (2006.01) ,C07K 14/705 (2006.01) ,A61K 39/395 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
52
Cytokines; Lymphokines; Interferons
525
Tumour necrosis factor (TNF)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants: MERRIMACK PHARMACEUTICALS, INC.[US/US]; One Kendall Square, Suite B7201 Cambridge, Massachusetts 02139, US
Inventors: SCHOEBERL, Birgit M.; US
TAM, Eric M.; US
Agent: BOTT, Cynthia M.; US
Priority Data:
62/453,31301.02.2017US
62/453,33801.02.2017US
62/453,35401.02.2017US
62/453,35701.02.2017US
62/453,37301.02.2017US
Title (EN) TNF SUPERFAMILY FUSION POLYPEPTIDES
(FR) POLYPEPTIDES DE FUSION DE LA SUPERFAMILLE DU TNF
Abstract:
(EN) Engineered 4-1BBL polypeptides and Fc-4-1BBL fusion polypeptides and methods for using such polypeptides and compositions to treat 4-1BB-related disorders (e.g., cancer). Engineered CD70 polypeptides and Fc-CD70 fusion polypeptides and methods for using such polypeptides and compositions to treat CD70-related disorders (e.g., cancer). Engineered GITRL polypeptides and Fc-GITRL fusion polypeptides and methods for using such polypeptides and compositions to treat GITRL-related disorders (e.g., cancer). Engineered OX40L polypeptides and Fc-OX40L fusion polypeptides and methods for using such polypeptides and compositions to treat OX40L-related disorders (e.g., cancer). Engineered CD40L polypeptides and Fc-CD40L fusion and methods for using such polypeptides and compositions to treat CD40L-related disorders (e.g., cancer). Engineered LIGHT polypeptides and Fc-LIGHT fusion polypeptides and methods for using such polypeptides and compositions to treat LIGHT-related disorders (e.g., cancer).
(FR) L'invention concerne des polypeptides 4-1BBL modifiés et des polypeptides de fusion Fc-4-1BBL, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à 4-1BB (par exemple, le cancer). L'invention concerne de plus des polypeptides CD70 modifiés et des polypeptides de fusion Fc-CD70, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à CD70 (par exemple, le cancer). L'invention concerne en outre des polypeptides GITRL modifiés et des polypeptides de fusion Fc-GITRL, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à GITRL (par exemple, le cancer). L'invention concerne également des polypeptides OX40L modifiés et des polypeptides de fusion Fc-OX40L, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à OX40L (par exemple, le cancer). L'invention concerne par ailleurs des polypeptides CD40L modifiés et des polypeptides de fusion Fc-CD40L, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés au CD40L (par exemple, le cancer). L'invention concerne de plus encore des polypeptides LIGHT modifiés et des polypeptides de fusion Fc-LIGHT, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés au LIGHT (par exemple, le cancer).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)